Actively Recruiting
Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
Led by University Hospital, Bordeaux · Updated on 2026-01-13
300
Participants Needed
15
Research Sites
259 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.
CONDITIONS
Official Title
Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF)
- Presence of JAK2V617F mutation with an allelic burden greater than 1%
- High risk of thrombosis defined by age over 60 years or prior thrombotic event
- Diagnosis of myeloproliferative neoplasm within the last 12 months
- Enrollment in the AVAJAK clinical trial and the FIMBANK biobank
- Affiliation with social security
- Signed informed consent
You will not qualify if you...
- Severe hepatic or renal insufficiency with creatinine clearance less than 30 ml/min
- Under legal protection such as guardianship or curatorship
- Receiving heparin treatment at the time of inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
CHU d'Angers, Service des maladies du Sang
Angers, France, 49933
Not Yet Recruiting
2
CH de la Côte Basque, Service Hématologie
Bayonne, France, 64100
Not Yet Recruiting
3
CHU de Bordeaux, Service Hématologie Biologique
Bordeaux, France, 33600
Not Yet Recruiting
4
CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire
Bordeaux, France, 33600
Not Yet Recruiting
5
CHU de Brest, Service Hématologie et Hémostase Clinique
Brest, France, 29609
Not Yet Recruiting
6
APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie Cellulaire
Créteil, France, 94010
Not Yet Recruiting
7
CHD de Vendée, Service Onco-hématologie
La Roche-sur-Yon, France, 85925
Not Yet Recruiting
8
APHP-Hôpital Bicêtre, Service Hématologie Clinique Ambulatoire
Le Kremlin-Bicêtre, France, 94270
Not Yet Recruiting
9
CH de Libourne, Service Hématologie
Libourne, France, 33505
Actively Recruiting
10
CHU de Limoges, Service Hématologie Clinique et de Thérapie Cellulaire
Limoges, France, 87042
Not Yet Recruiting
11
CH des Pays de Morlaix, Service Onco-Hématologie
Morlaix, France, 29672
Not Yet Recruiting
12
CHU de Nantes, Service Hématologie Clinique
Nantes, France, 44093
Not Yet Recruiting
13
Hôpital Privé du Confluent, Service Hématologie
Nantes, France, 44202
Not Yet Recruiting
14
APHO-Hôpital Saint-Louis, Centre d'Investigations Cliniques
Paris, France, 75010
Not Yet Recruiting
15
CH de Roubaix, Service Hématologie
Roubaix, France, 59100
Not Yet Recruiting
Research Team
A
Alexandre GUY
CONTACT
C
Chloé JAMES
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here